tbuckley/cabot-search huggingface dataset:
Regulation of uncoupling protein-2 (UCP-2) expression in human glioma cells by peroxisome proliferators-activated receptor (PPAR) agonists
Authors: James E. P. Brown, John L. Darling, Simon J. Dunmore, S. Bassey
Journal: Neuro-Oncology (2005)

Abstracts from Neuro-Oncology are provided here courtesy of
Society for Neuro-Oncology and Duke University Press
Autophagy Genes Enhance Murine Gammaherpesvirus 68 Reactivation from Latency by Preventing Virus-Induced Systemic Inflammation
Authors: Sunmin Park, Michael D. Buck, Chandni Desai, Xin Zhang, Ekaterina Loginicheva, Jennifer Martinez, Michael L. Freeman, Tatsuya Saitoh, Shizuo Akira, Jun-Lin Guan, You-Wen He, Marcia A. Blackman, Scott A. Handley, Beth Levine, Douglas R. Green, Tiffany A. Reese, Maxim N. Artyomov, Herbert W. Virgin
Journal: Cell Host & Microbe (2016)
Comparison of the 2007 and 2013 Asco/Cap Guidelines for Her2 Ish Testing in Invasive Breast Cancer Patients
Authors: M. Salido, A. Puiggros, J.M. Corominas, M. Iglesias, M. Rodriguez-Rivera, C. Melero, I. Tusquets Trias Bes, J. Albanell, S. Serrano, S. Servitja Tormo, B. Espinet
Journal: Annals of Oncology (2014)
Impact of radical bowel resection on survival in advanced epithelial ovarian cancer
Authors: M. Arora, S. Saha, A. Puthillath, R. Sehgal, N. Dutt, J. Metz, A. Misra, M. Perez, D. Wiese, T. Singh
Journal: Journal of Clinical Oncology (2005)

5166 Background: Ovarian cancer (OvCa) most often presents in advanced stages (III and IV) with overall survival of less than 35%. A significant number of these patients (pts) have bowel involvement (BI) at the time of diagnosis. Extensive debulking is required for optimal management of advanced OvCa. However, there is debate regarding the role of radical bowel resection (BR) on the impact of survival. We did a retrospective study to see impact of radical BR at initial operation on the survival of pts with advanced OvCa. Methods: A retrospective chart review was done for 203 consecutive pts with diagnosis of primary OvCa between August 1991 to November 2002. Fifty one pts with OvCa and radical BR (advanced stage III C and IV) were included in the study. All pts underwent cytoreductive surgery with BR with intent to maximum debulking. Data were obtained for surgery,recurrence and survival. Results: There were 51 pts who underwent radical BR during primary OvCa debulking. Median age of patients was 64 yrs (Range 44–89 yrs). Median follow up was 84 months (Range 28–159 months). Of the 51 pts, 20 had colorectal (Cr), 12 had small bowel (Sb), 19 had both CR and Sb resection. Bowel continuity was achieved primarily in 67% of pts. All pts underwent systemic chemotherapy with six cycles of carboplatin and Taxol as first line of treatment. Overall mean survival was 32 months. 2yrs disease free survival was 63%. Mean survival of pts with recurrence was 31.5 months versus 38.1 months for pts without recurrence. Recurrence developed in 37% of pts during followup period.There was no surgical mortality within 30 days in this series. Conclusions: Maximum debulking which includes BR appears beneficial for pts with advanced OvCa.Suboptimal resection rarely achieves cure. During primary OvCa debulking, if bowel involvements are found,radical debulking with BR may further prolong the disease free and overall survival. No significant financial relationships to disclose.
Clinical Impact of CD25 Expression of Leukemic Blasts on Subsequent Transplant Outcomes in Patients with Refractory or Relapsed Acute Myeloid Leukemia
Authors: Shuntaro Ikegawa, Noriko Doki, Keita Yamamoto, Yutaro Hino, Kaito Harada, Naoki Shingai, Ken Watanabe, Yasushi Senoo, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi
Journal: Blood (2014)
Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.
Authors: R Chopra, A H Goldstone, A K McMillan, R Powles, A G Smith, H G Prentice, C Reid, R Marcus, A Bell, D Milligan
Journal: Journal of Clinical Oncology (1991)

The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis (four patients; one fatal), intracranial hemorrhage (two patients; two fatal) has occurred. There have been four procedure-related deaths (12%). Hematologic recovery was satisfactory for neutrophils (median time to 0.5 x 10(9)/L, 22 days [range, 11 to 101 days]), but very slow for platelets (median time to 50 x 10(9)/L, 62 days [range, 15 to 1,080 days]). This study suggests that the use of Bu/Cy with ABMT for patients beyond first remission in AML compares favorably with chemotherapy, and although the procedure-related mortality is acceptable, it is associated with protracted platelet recovery.
Early Ofatumumab Treatment For High-Risk, Treatment-Naive Patients With Chronic Lymphocytic Leukemia
Authors: Nitin Jain, Michael J. Keating, Alessandra Ferrajoli, Marina Konopleva, Deborah A. Thomas, Naveen Pemmaraju, Courtney D. DiNardo, Susan O'Brien, William G. Wierda
Journal: Blood (2013)
WHO confirms new case of Ebola in Sierra Leone
Authors: Anne Gulland
Journal: BMJ (2016)

The World Health Organization has confirmed a new case of Ebola virus disease in Sierra Leone, just a day after it declared the end of transmission of the virus in west Africa.1

Barely 24 hours after it declared Liberia free of the disease, WHO said that there had been a new case of the disease in the northern district of Tonkolili. Sierra Leone was officially declared Ebola free on 7 …
Prognostic Significance of Tissue Oxygen Saturation Using Near Infrared Spectroscopy in Patients Undergoing Therapeutic Hypothermia After Cardiac Arrest
Authors: DO Adrian C Bell, Ataul Qureshi, Stephen Awuor, Sanjeev U Nair, Agei Enoh, DO Daniel J Makowski, Mph Charity Curtis, Facc Nainesh Patel, Bruce Feldman, Do, Facc
Journal: Circulation (2015)

Background: Near infrared spectroscopy is a noninvasive method for assessing regional tissue oxygenation (StO2), a parameter influenced by microvascular perfusion. Normal StO2 values recorded from ...
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
Authors: M Fulciniti, N Amodio, R L Bandi, A Cagnetta, M K Samur, C Acharya, R Prabhala, P D'Aquila, D Bellizzi, G Passarino, S Adamia, A Neri, Z R Hunter, S P Treon, K C Anderson, P Tassone, N C Munshi
Journal: Blood Cancer Journal (2016)

Abstract Deregulated microRNA (miR)/transcription factor (TF)-based networks represent a hallmark of cancer. We report here a novel c-Myc/miR-23b/Sp1 feed-forward loop with a critical role in multiple myeloma (MM) and Waldenstrom’s macroglobulinemia (WM) cell growth and survival. We have found miR-23b to be downregulated in MM and WM cells especially in the presence of components of the tumor bone marrow milieu. Promoter methylation is one mechanism of miR-23b suppression in myeloma. In gain-of-function studies using miR-23b mimics-transfected or in miR-23b-stably expressing MM and WM cell lines, we observed a significant decrease in cell proliferation and survival, along with induction of caspase-3/7 activity over time, thus supporting a tumor suppressor role for miR-23b. At the molecular level, miR-23b targeted Sp1 3′UTR and significantly reduced Sp1-driven nuclear factor-κB activity. Finally, c-Myc, an important oncogenic transcription factor known to stimulate MM cell proliferation, transcriptionally repressed miR-23b. Thus MYC -dependent miR-23b repression in myeloma cells may promote activation of oncogenic Sp1-mediated signaling, representing the first feed-forward loop with critical growth and survival role in myeloma.
25-Hydroxyvitamin D in Patients With Cognitive Decline
Authors: Sevilay Muratli, Ozlem Soyluk, Fatih Tufan
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
WITHDRAWN: Tumor-targeting siRNA delivery utilizing of folate-PEG appended dendrimer (G4) conjugate with α-cyclodextrin
Authors: Ayumu Ohyama, Taishi Higashi, Keiichi Motoyama, Hidetoshi Arima
Journal: Asian Journal of Pharmaceutical Sciences (2015)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Sex Versus Gender-Related Characteristics
Authors: Roxanne Pelletier, Nadia A. Khan, Jafna Cox, Stella S. Daskalopoulou, Mark J. Eisenberg, Simon L. Bacon, Kim L. Lavoie, Kaberi Daskupta, Doreen Rabi, Karin H. Humphries, Colleen M. Norris, George Thanassoulis, Hassan Behlouli, Louise Pilote
Journal: Journal of the American College of Cardiology (2016)
Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models
Authors: Kari Pollock, Heather Dahlenburg, Haley Nelson, Kyle D Fink, Whitney Cary, Kyle Hendrix, Geralyn Annett, Audrey Torrest, Peter Deng, Joshua Gutierrez, Catherine Nacey, Karen Pepper, Stefanos Kalomoiris, Johnathon D Anderson, Jeannine McGee, William Gruenloh, Brian Fury, Gerhard Bauer, Alexandria Duffy, Theresa Tempkin, Vicki Wheelock, Jan A Nolta
Journal: Molecular Therapy (2016)

Huntington's disease (HD) is a fatal degenerative autosomal dominant neuropsychiatric disease that causes neuronal death and is characterized by progressive striatal and then widespread brain atrophy. Brain-derived neurotrophic factor (BDNF) is a lead candidate for the treatment of HD, as it has been shown to prevent cell death and to stimulate the growth and migration of new neurons in the brain in transgenic mouse models. BDNF levels are reduced in HD postmortem human brain. Previous studies have shown efficacy of mesenchymal stem/stromal cells (MSC)/BDNF using murine MSCs, and the present study used human MSCs to advance the therapeutic potential of the MSC/BDNF platform for clinical application. Double-blinded studies were performed to examine the effects of intrastriatally transplanted human MSC/BDNF on disease progression in two strains of immune-suppressed HD transgenic mice: YAC128 and R6/2. MSC/BDNF treatment decreased striatal atrophy in YAC128 mice. MSC/BDNF treatment also significantly reduced anxiety as measured in the open-field assay. Both MSC and MSC/BDNF treatments induced a significant increase in neurogenesis-like activity in R6/2 mice. MSC/BDNF treatment also increased the mean lifespan of the R6/2 mice. Our genetically modified MSC/BDNF cells set a precedent for stem cell-based neurotherapeutics and could potentially be modified for other neurodegenerative disorders such as amyotrophic lateral sclerosis, Alzheimer's disease, and some forms of Parkinson's disease. These cells provide a platform delivery system for future studies involving corrective gene-editing strategies.
Response to Letter Regarding Article, “Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007: Analysis of 5-Year Citation Rates”
Authors: Isuru Ranasinghe, Abbas Shojaee, Behnood Bikdeli, Aakriti Gupta, Ruijun Chen, Joseph S. Ross, Frederick A. Masoudi, John A. Spertus, Brahmajee K. Nallamothu, Harlan M. Krumholz
Journal: Circulation (2016)
Doctors and patients express concern over prospect of physician assisted death
Authors: Anne Gulland
Journal: BMJ (2016)

Doctors and members of the UK public are concerned at the prospect of legalisation of physician assisted dying, research commissioned by the BMA has found.1

The qualitative study, which was based on in-depth discussion with 237 doctors and 269 members of the public, found that many members of the public were uninformed about the issue. However, after being given background information on the topic, doctors and patients expressed shock and surprise about complications, failure, and the length of time it could take to die, particularly when they were told of the case of a patient in …
Warfarin anticoagulation for small-cell lung cancer: evidence against a cytotoxic or anticoagulant mechanism.
Authors: J M Silberberg, S Zucker
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.1.182 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2153191 Warfarin anticoagulation for small-cell lung cancer: evidence against a cytotoxic or anticoagulant mechanism. J M SilberbergxJ M SilberbergSearch for articles by this author , S ZuckerxS ZuckerSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.1.182 First Page PDF © 1990 by American Society of Clinical Oncology
Apoptosis-Inducing-Factor-Dependent Mitochondrial Function Is Required for T Cell but Not B Cell Function
Authors: Sandra Milasta, Christopher P. Dillon, Oliver E. Sturm, Katherine C. Verbist, Taylor L. Brewer, Giovanni Quarato, Scott A. Brown, Sharon Frase, Laura J. Janke, S. Scott Perry, Paul G. Thomas, Douglas R. Green
Journal: Immunity (2016)
Confusional paranoid psychosis after withdrawal from sympathomimetic amines: two case reports
Authors: J Deveaugh-Geiss, A Pandurangi
Journal: American Journal of Psychiatry (1982)

Paranoid psychosis may result from intoxication with, or withdrawal from amphetamines. The authors describe two cases of paranoid confusional psychosis commencing 1 week after the patients' withdrawal from sympathomimetic amines. The pathophysiology for this unusual disorder may be agonist-induced dopamine receptor hypersensitivity.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Authors: Valeria Magarotto, Sara Bringhen, Massimo Offidani, Giulia Benevolo, Francesca Patriarca, Roberto Mina, Antonietta Pia Falcone, Lorenzo De Paoli, Giuseppe Pietrantuono, Silvia Gentili, Caterina Musolino, Nicola Giuliani, Annalisa Bernardini, Concetta Conticello, Stefano Pulini, Giovannino Ciccone, Vladimír Maisnar, Marina Ruggeri, Renato Zambello, Tommasina Guglielmelli, Antonio Ledda, Anna Marina Liberati, Vittorio Montefusco, Roman Hajek, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2016)
Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus
Authors: Jie Yao, Lin Leng, Maor Sauler, Weiling Fu, Junsong Zheng, Yi Zhang, Xin Du, Xiaoqing Yu, Patty Lee, Richard Bucala
Journal: Journal of Clinical Investigation (2016)

The immunoregulatory cytokine macrophage migration inhibitory factor (MIF) is encoded in a functionally polymorphic locus that is linked to the susceptibility of autoimmune and infectious diseases. The MIF promoter contains a 4-nucleotide microsatellite polymorphism (-794 CATT) that repeats 5 to 8 times in the locus, with greater numbers of repeats associated with higher mRNA levels. Because there is no information about the transcriptional regulation of these common alleles, we used oligonucleotide affinity chromatography and liquid chromatography-mass spectrometry to identify nuclear proteins that interact with the -794 CATT5-8 site. An analysis of monocyte nuclear lysates revealed that the transcription factor ICBP90 (also known as UHRF1) is the major protein interacting with the MIF microsatellite. We found that ICBP90 is essential for MIF transcription from monocytes/macrophages, B and T lymphocytes, and synovial fibroblasts, and TLR-induced MIF transcription is regulated in an ICBP90- and -794 CATT5-8 length-dependent manner. Whole-genome transcription analysis of ICBP90 shRNA-treated rheumatoid synoviocytes uncovered a subset of proinflammatory and immune response genes that overlapped with those regulated by MIF shRNA. In addition, the expression levels of ICBP90 and MIF were correlated in joint synovia from patients with rheumatoid arthritis. These findings identify ICBP90 as a key regulator of MIF transcription and provide functional insight into the regulation of the polymorphic MIF locus.
Abstract P4-01-18: The relationship between components of tumour inflammatory cell infiltration and hematogenous metastasis in patients with primary breast cancer
Authors: Naping Wu, Jue Wang, Tiansong Xia, Wenbin Zhou, Zhao Liu, Yi Zhao, Xiaoan Liu, Xiaoming Zha, Shui Wang
Journal: Cancer Research (2015)

Abstract Background: Tumors are infiltrated by inflammatory cells (e.g. macrophages, B and T lymphocytes), which may promote tumor growth and invasion. However, the clinical correlation between hematogenous metastasis and relative amount of inflammatory cells is still unknown. Methods: The prevalence of circulating tumor cells (CTC) in peripheral blood of 133 breast cancer patients was detected by a multimarker comprised of cytokeratin 19 (CK19), small breast epithelial mucin (SBEM) and human mammaglobin (hMAM) real time quantitative RT-PCR (QPCR) platform. Meanwhile, CD68+macrophages, CD20+B lymphocytes and CD3+T lymphocytes at the peritumor and intratumor were also counted by immunohistochemical examination, in corresponding primary invasive breast carcinomas. The relationship between CTC in peripheral blood and inflammatory cell infiltration was analyzed. Results: The positive rate of CTC was 39.8% (53 out of 133). The prevalence of CTC in peripheral blood was only observed in invasive breast carcinomas. There were more inflammatory cells at the peritumor than the tumor center (P &amp;lt; 0.001).In addition, higher total numbers of infiltrating both CD68+macrophages and CD3+T lymphocytes were associated with significantly the prevalence of CTC in peripheral blood (P &amp;lt; 0.05). Conclusion: Our data support a hypothesis that CD68+macrophage and CD3+T lymphocyte infiltrating in the breast cancer microenvironment may promote tumor cells disseminating through circulation system. Citation Format: Naping Wu, Jue Wang, Tiansong Xia, Wenbin Zhou, Zhao Liu, Yi Zhao, Xiaoan Liu, Xiaoming Zha, Shui Wang. The relationship between components of tumour inflammatory cell infiltration and hematogenous metastasis in patients with primary breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-01-18.
Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: a Grupo Argentino de Tratamiento de la Leucemia Aguda study.
Authors: C Corrado, M T Santarelli, S Pavlovsky, M Pizzolato
Journal: Journal of Clinical Oncology (1989)

Four hundred ten previously untreated multiple myeloma patients entered onto two consecutive Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA) protocols were analyzed to identify significant prognostic factors influencing survival. The univariate analysis selected the following variables: performance status, renal function, percentage of bone marrow plasma cells at diagnosis, hemoglobin, and age. A multivariate analysis showed that performance status, renal function, percentage of bone marrow plasma cells, hemoglobin, and age were the best predictive variables for survival. A score was assigned to each patient according to these variables, which led to their classification in three groups: good, intermediate, and poor risk, with a probability of survival of 26% and 10% at 96 months, and 5% at 56 months, and median survival of 60, 37, and 14 months, respectively (P = .0000). In our patient population, this model proved to be superior to the Durie-Salmon staging system in defining prognostic risk groups, and separating patients with significantly different risks within each Durie-Salmon stage.
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma
Authors: Robert Hiensch, Klaus Meinhof, Desh Nandedkar, Glen Chun, Sakshi Dua
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Figure 1. Computed tomography of the chest on axial cuts (left) and sagittal cuts (right) at 10-week follow-up demonstrates central reticular and ground-glass opacities with sparing of both the perihilar and subpleural regions. A 56-year-old man with hepatitis B virus– associated cirrhosis and advanced hepatocellular carcinoma (HCC) presented with dyspnea. He was on therapy with sorafenib and had undergone radioembolization with yttrium 90 (Y) 5 days prior, which was complicated by a high shunt fraction (45%) resulting in an excessive lung radiation exposure of 55 Gy. A technetium-99m macroaggregated albumin (Tc-MAA) scan 1 week prior had demonstrated only a 22% shunt fraction, which would have resulted in a lung radiation dose of less than 30 Gy, the accepted safety standard. Although the initial chest radiograph was normal, given the patient’s symptoms of dyspnea and high dose of radiation exposure, empiric prednisone was prescribed at a dose of 20 mg daily in hopes of preventing radiation pneumonitis (RP). At 1 month follow-up, computed tomography of the chest was normal. Five weeks later, the patient was admitted with worsening dyspnea, and repeat computed tomography demonstrated bilateral ground-glass opacities with sparing of the perihilar regions and periphery (Figure 1). Bronchoscopy with bronchoalveolar lavage and multiple transbronchial biopsies in the affected region were negative for metastatic disease and did not identify any infectious organisms, including Pneumocystis, on special stains and molecular techniques. Histology showed nonspecific inflammation (Figure 2). Sorafenib was discontinued, and the glucocorticoid dose was increased to intravenous methylprednisolone at 60mg daily (equivalent to 1 mg/kg/d) for presumed RP. The patient continued to deteriorate despite therapy, Figure 2. Transbronchial biopsy yielded a 0.43 0.23 0.1–cm sample of alveolar tissue with anthracotic pigment deposition and minor inflammation with no granulomas, malignancy, or microorganisms seen. Cultures were negative (hematoxylin and eosin, 3100).